🇺🇸 FDA
Patent

US 11466274

Modified gapmer oligonucleotides and methods of use

granted A61KA61K31/7088A61K31/7125

Quick answer

US patent 11466274 (Modified gapmer oligonucleotides and methods of use) held by Aligos Therapeutics, Inc. expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aligos Therapeutics, Inc.
Grant date
Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/7088, A61K31/7125, A61P, A61P31/20